Total Funding
37
45
Total FundingPost-IPO Equity raised
Growth Score
-12 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
66703
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
- Eric Huang: Senior Vice President of Global Corporate Development and Finance
- Dajun Yang: President ,Chairman of the Board, Executive Director & Chief Executive Officer
About the Company
Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors.
